数据
资源
版本对比
免费注册
预约演示
免费注册
Sight Sciences
to Present at the Upcoming 23rd Annual Needham Healthcare Conference
2024-03-26
·
BioSpace
MENLO PARK, Calif., March 26, 2024 (GLOBE NEWSWIRE) --
Sight Sciences, Inc.
, (Nasdaq: SGHT) (“
Sight Sciences
” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will present at the upcoming 23rd Annual Needham Healthcare Conference being held virtually.
Sight Sciences
’ management is scheduled to present on Tuesday, April 9, 2024, at 12:45 pm PT / 3:45 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: investors.sightsciences.com. About
Sight Sciences
Sight Sciences
is an eyecare technology company focused on developing and commercializing innovative and interventional technologies intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent
eye diseases
,
Sight Sciences
seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's
OMNI
® Surgical System is an implant-free
glaucoma
surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with
primary open-angle glaucoma
; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm’s canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with
open-angle glaucoma
.
Glaucoma
is the world's leading cause of
irreversible blindness
. The Company's TearCare® System technology is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with
evaporative dry eye disease
due to meibomian gland dysfunction (“MGD”) when used in conjunction with manual expression of the meibomian glands, enabling clearance of gland obstructions by physicians to address the leading cause of
dry eye disease
. The Company's SION® Surgical Instrument is a manually operated device available in the United States to be used in ophthalmic surgical procedures to excise trabecular meshwork. For more information, visit investors.sightsciences.com.
Sight Sciences
and TearCare are trademarks of
Sight Sciences
registered in the United States.
OMNI
, OMNI ERGO, and SION are trademarks of
Sight Sciences
registered in the United States, European Union and other territories. © 2024
Sight Sciences
. All rights reserved. Media contact: pr@SightSciences.com Investor contact: Philip Taylor Gilmartin Group 415.937.5406 Investor.Relations@Sightsciences.com
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Sight Sciences, Inc.
上海欧米尼医药科技有限公司
适应症
眼部疾病
青光眼
开角型青光眼
[+2]
靶点
-
药物
-
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务